Likewise, the deletion of the m6A demethylase ALKBH5 sensitized tumors to cancer immunotherapy, suggesting that ALKBH5 may be a potential target to improve the outcome of immunotherapy for melanomas, CRC, and other underlying cancers [106]. This evidence concerns the gene ALKBH5 and melanoma.